Communiqués AstraZeneca PLC Nasdaq Stockholm

Actions

AZN

GB0009895292

Marché Fermé - Nasdaq Stockholm Autres places de cotation 17:29:41 05/06/2024			Varia. 5j.	Varia. 1 janv.
1 676 ^SEK	+0,81 %		+3,68 %	+23,86 %

05/06	ASTRAZENECA PLC : HSBC toujours positif	ZM
05/06	Le ministère de la Santé d'Abou Dhabi et AstraZeneca élargissent leur partenariat lors de la BIO International Convention 2024 pour créer un nouveau centre d'excellence pour les maladies rares	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Astrazeneca completes £1.5bn Fusion Pharmaceuticals deal	07:21	AQ
AstraZeneca - Acquisition of Fusion completed	05/06	AQ
AstraZeneca : Biographies	03/06	PU
AstraZeneca : BLOCK LISTING SIX MONTHLY RETURN - Form 6-K	03/06	PU
AstraZeneca : Transparency Directive - Form 6-K	03/06	PU
AstraZeneca immunotherapy could boost lung cancer survival	03/06	AQ
AstraZeneca : Tagrisso with the addition of chemotherapy recommended for approval in the EU by CHMP for patients with EGFR-mutated advanced lung cancer - Form 6-K	03/06	PU
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial	02/06	BU
AstraZeneca : Tagrisso reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial	02/06	PU
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo	02/06	BU
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy	02/06	BU
Daiichi Sankyo - Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial	28/05	AQ
Expansion of AstraZeneca's flagship health equity programme Healthy Heart Africa	28/05	AQ
Expansion of AstraZeneca’s flagship health equity programme Healthy Heart Africa The programme aims to improve health outcomes, with a focus on increasing awareness of the symptoms and risks of hypertension	28/05	AQ
Le datopotamab deruxtecan a montré une survie globale cliniquement significative par rapport à la chimiothérapie chez des patients atteints d'un cancer avancé du poumon non à petites cellules et non squameux	27/05	BU
Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial	27/05	BU
AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)	23/05	BU
AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024	22/05	BU
Astrazeneca looks to double revenue in 'new era of growth'	22/05	AQ
INSIDE XP POWER REJECTS BID ...	22/05	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

ASTRAZENECA : Un premier trimestre solide permet d'espérer une révision à la hausse des prévisions

Le 25 avril 2024 à 18:02

Une autre bonne année en perspective pour AstraZeneca : Pascal Soriot, PDG

Le 09 février 2023 à 16:04